EuroSCORE II and the STS score are more accurate in transapical than in transfemoral transcatheter aortic valve implantation

被引：18

作者：

Kofler, Markus ^{[1
]}

Reinstadler, Sebastian J. ^{[2
]}

Stastny, Lukas ^{[1
]}

Dumfarth, Julia ^{[1
]}

Reindl, Martin ^{[2
]}

Wachter, Kristina ^{[3
]}

Rustenbach, Christian J. ^{[3
]}

Mueller, Silvana ^{[2
]}

Feuchtner, Gudrun ^{[4
]}

Friedrich, Guy ^{[2
]}

Metzler, Bernhard ^{[2
]}

Grimm, Michael ^{[1
]}

Bonaros, Nikolaos ^{[1
]}

Baumbach, Hardy ^{[3
]}

机构：

[1] Med Univ Innsbruck, Univ Clin Cardiac Surg, Anichstr 35, A-6020 Innsbruck, Austria

[2] Med Univ Innsbruck, Univ Clin Internal Med Cardiol & Angiol 3, Innsbruck, Austria

[3] Robert Bosch Krankenhaus, Dept Cardiovasc Surg, Stuttgart, Germany

[4] Med Univ Innsbruck, Univ Clin Radiol, Innsbruck, Austria

来源：

INTERACTIVE CARDIOVASCULAR AND THORACIC SURGERY | 2018年 / 26卷 / 03期

关键词：

Risk prediction in transcatheter aortic valve implantation; European System for Cardiac Operative Risk Evaluation II; Society of Thoracic Surgeons score; Transcatheter aortic valve implantation; Access site; THORACIC SURGEONS SCORE; LOGISTIC EUROSCORE; LATE MORTALITY; RISK; SOCIETY; PERFORMANCE; PREDICTION; VALIDATION;

D O I：

10.1093/icvts/ivx343

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

OBJECTIVES: The European System for Cardiac Operative Risk Evaluation II (EuroSCORE II) and the Society of Thoracic Surgeons (STS) score are currently used to estimate periprocedural risk of death in patients undergoing transcatheter aortic valve implantation (TAVI). However, data regarding the predictive ability and usefulness of these scores for TAVI are controversial, especially for different access sites. METHODS: Between 2008 and 2016, 1192 consecutive patients undergoing TAVI [transfemoral (TF): n = 607 (51%); transapical (TA): n = 585 (49%)] at 2 centres were included. All-cause mortality was assessed at a median of 533 days (interquartile range 153-1036). The value of the EuroSCORE II and the STS score in terms of predicting 30-day and cumulative mortality according to access site was investigated. RESULTS: The mean age was 83 interquartile range 79-86) years. Overall, the 30-day mortality rate was 7.6% n = 90), and the cumulative all-cause mortality rate was 35.1% n = 418). The EuroSCORE II and the STS score were significantly increased in non-survivors compared with survivors P < 0.001). The EuroSCORE II and the STS score emerged as independent predictors of 30-day mortality [EuroSCORE II: odds ratio OR) 1.039, 95% confidence interval CI) 1.013-1.065; P = 0.003; STS score: OR 1.055, 95% CI 1.023-1.088; P = 0.001] and cumulative all-cause mortality [EuroSCORE II: hazard ratio HR) 1.026, 95% CI 1.013-1.038; P < 0.001; STS score: HR 1.05, 95% CI 1.03-1.06; P < 0.001]. In contrast to TF TAVI, the EuroSCORE II OR 1.038, 95% CI 1.009-1.068; P = 0.010) and the STS score OR: 1.063, 95% CI 1.0251.102; P = 0.001) were independent predictors of 30-day mortality and cumulative mortality EuroSCORE II: HR 1.023, 95% CI 1.009-1.037; P = 0.001; STS score: HR 1.055, 95% CI 1.037-1.073; P < 0.001) in patients undergoing TA TAVI. CONCLUSIONS: The EuroSCORE II and the STS score were independent predictors of 30-day and cumulative mortality rates in patients undergoing TAVI. The EuroSCORE II and the STS score were associated with 30-day mortality and mortality during follow-up period only in TA TAVI.

引用

页码：413 / 419

页数：7

共 26 条

[1] Statistics notes - The cost of dichotomising continuous variables [J].